A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic Disorders
Patent No. EP4358995 (titled "A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic Disorders") was filed by Scholar Rock on Jun 22, 2022. The application was issued on Dec 3, 2025.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4358995
- Application Number
- EP22744054A
- Filing Date
- Jun 22, 2022
- Status
- Granted And Under Opposition
- Oct 31, 2025
- Publication Date
- Dec 3, 2025
- External Links
- Slate, Register , Google Patents